Baxter International (Baxter International) COGS-to-Revenue : 0.62 (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Baxter International COGS-to-Revenue?

Baxter International's Cost of Goods Sold for the three months ended in Dec. 2023 was $2,413 Mil. Its Revenue for the three months ended in Dec. 2023 was $3,885 Mil.

Baxter International's COGS to Revenue for the three months ended in Dec. 2023 was 0.62.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Baxter International's Gross Margin % for the three months ended in Dec. 2023 was 37.89%.

Baxter International COGS-to-Revenue Historical Data

The historical data trend for Baxter International's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International COGS-to-Revenue Chart

Baxter International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.58

0.61

0.65

0.66

Baxter International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.63	0.63	0.70	0.70	0.62

Baxter International COGS-to-Revenue Calculation

Baxter International's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	9838	/	14813
	=	0.66

Baxter International's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2413	/	3885
	=	0.62

Baxter International (NYSE:BAX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Baxter International's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2413 / 3885
	=	37.89 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Baxter International COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Baxter International's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Baxter International (Baxter International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

1BAX:Italy BTL:Germany BTL:Germany BTL:Germany BAX:Austria

Address

One Baxter Parkway, Deerfield, IL, USA, 60015

Website

https://www.baxter.com

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.

Executives

Joel T. Grade	officer: EVP, Chief Financial Officer	SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth	officer: EVP, Group Pres, Kidney Care	1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L	director	BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul	officer: EVP, Group Pres, Healthcare	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig	officer: EVP, Group President, Pharm	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight	officer: EVP, Group Pres, Medical	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler	officer: SVP, Chief Quality Officer	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jeanne K Mason	officer: CVP, Human Resources	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn	officer: SVP, President, APAC	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver	director
David Brent Shafer	director	2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Amy Mcbride Wendell	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Cathy R Smith	director	TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403